Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

Laura Bonanno, Carlota Costa, Margarita Majem, Jose Javier Sanchez, Ignacio Rodriguez, Ana Gimenez-Capitan, Miquel Angel Molina-Vila, Alain Vergnenegre, Bartomeu Massuti, Adolfo Favaretto, Massimo Rugge, Cinta Pallares, Miquel Taron, Rafael Rosell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model. Methods: We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point. Results: The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0-1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004). Conclusions: These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model.

Original languageEnglish
Article number312
JournalBMC Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - May 14 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Platinum
Messenger RNA
DNA Damage
Lung Neoplasms
Ubiquitin-Protein Ligases
Homologous Recombination
DNA Repair
Paraffin
Disease-Free Survival
Real-Time Polymerase Chain Reaction
Multivariate Analysis
Drug Therapy
Survival
Population
Genes
Neoplasms
Proteins

Keywords

  • BRCA1
  • DNA repair
  • HERC2
  • Non-small-cell lung cancer
  • Platinum
  • Predictive markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Bonanno, L., Costa, C., Majem, M., Sanchez, J. J., Rodriguez, I., Gimenez-Capitan, A., ... Rosell, R. (2016). Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. BMC Cancer, 16(1), [312]. https://doi.org/10.1186/s12885-016-2339-5

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. / Bonanno, Laura; Costa, Carlota; Majem, Margarita; Sanchez, Jose Javier; Rodriguez, Ignacio; Gimenez-Capitan, Ana; Molina-Vila, Miquel Angel; Vergnenegre, Alain; Massuti, Bartomeu; Favaretto, Adolfo; Rugge, Massimo; Pallares, Cinta; Taron, Miquel; Rosell, Rafael.

In: BMC Cancer, Vol. 16, No. 1, 312, 14.05.2016.

Research output: Contribution to journalArticle

Bonanno, L, Costa, C, Majem, M, Sanchez, JJ, Rodriguez, I, Gimenez-Capitan, A, Molina-Vila, MA, Vergnenegre, A, Massuti, B, Favaretto, A, Rugge, M, Pallares, C, Taron, M & Rosell, R 2016, 'Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer', BMC Cancer, vol. 16, no. 1, 312. https://doi.org/10.1186/s12885-016-2339-5
Bonanno, Laura ; Costa, Carlota ; Majem, Margarita ; Sanchez, Jose Javier ; Rodriguez, Ignacio ; Gimenez-Capitan, Ana ; Molina-Vila, Miquel Angel ; Vergnenegre, Alain ; Massuti, Bartomeu ; Favaretto, Adolfo ; Rugge, Massimo ; Pallares, Cinta ; Taron, Miquel ; Rosell, Rafael. / Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. In: BMC Cancer. 2016 ; Vol. 16, No. 1.
@article{366317c0cd434bf893664facb32c17fb,
title = "Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer",
abstract = "Background: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model. Methods: We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point. Results: The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0-1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004). Conclusions: These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model.",
keywords = "BRCA1, DNA repair, HERC2, Non-small-cell lung cancer, Platinum, Predictive markers",
author = "Laura Bonanno and Carlota Costa and Margarita Majem and Sanchez, {Jose Javier} and Ignacio Rodriguez and Ana Gimenez-Capitan and Molina-Vila, {Miquel Angel} and Alain Vergnenegre and Bartomeu Massuti and Adolfo Favaretto and Massimo Rugge and Cinta Pallares and Miquel Taron and Rafael Rosell",
year = "2016",
month = "5",
day = "14",
doi = "10.1186/s12885-016-2339-5",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

AU - Bonanno, Laura

AU - Costa, Carlota

AU - Majem, Margarita

AU - Sanchez, Jose Javier

AU - Rodriguez, Ignacio

AU - Gimenez-Capitan, Ana

AU - Molina-Vila, Miquel Angel

AU - Vergnenegre, Alain

AU - Massuti, Bartomeu

AU - Favaretto, Adolfo

AU - Rugge, Massimo

AU - Pallares, Cinta

AU - Taron, Miquel

AU - Rosell, Rafael

PY - 2016/5/14

Y1 - 2016/5/14

N2 - Background: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model. Methods: We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point. Results: The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0-1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004). Conclusions: These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model.

AB - Background: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model. Methods: We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point. Results: The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0-1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004). Conclusions: These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model.

KW - BRCA1

KW - DNA repair

KW - HERC2

KW - Non-small-cell lung cancer

KW - Platinum

KW - Predictive markers

UR - http://www.scopus.com/inward/record.url?scp=84969222374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969222374&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2339-5

DO - 10.1186/s12885-016-2339-5

M3 - Article

AN - SCOPUS:84969222374

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 312

ER -